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Abstract
Background: Anemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in patients with 
chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESA) are commonly used to increase hemoglobin 
levels in this population. In observational studies, higher hemoglobin levels (around 11-13 g/dL) are associated with 
improved survival and quality of life compared to hemoglobin levels around 9-10 g/dL. A systematic review of 
randomized trials found that targeting higher hemoglobin levels with ESA causes an increased risk of adverse vascular 
outcomes. It is possible, but has never been formally tested in a randomized trial, that ESA dose rather than targeted 
hemoglobin concentration itself mediates the increased risk of adverse vascular outcomes. The Clinical Evaluation of 
the DOSe of Erythropoietins (C.E. DOSE) trial will assess the benefits and harms of a high versus a low fixed ESA dose for 
the management of anemia in patients with end stage kidney disease.
Methods/Design: This is a randomized, prospective open label blinded end-point (PROBE) trial due to enrol 2204 
hemodialysis patients in Italy. Patients will be randomized 1:1 to 4000 IU/week versus 18000 IU/week of intravenous 
epoietin alfa or beta, or any other ESA in equivalent doses. The dose will be adjusted only if hemoglobin levels fall 
outside the 9.5-12.5 g/dL range. The primary outcome will be a composite of all-cause mortality, non fatal stroke, non 
fatal myocardial infarction and hospitalization for cardiovascular causes. Quality of life and costs will also be assessed.
Discussion: The C.E.DOSE study will help inform the optimal therapeutic strategy for the management of anemia of 
hemodialysis patients, improving clinical outcomes, quality of life and costs, by ascertaining the potential benefits and 
harms of different fixed ESA doses.
Trial registration: Clinicaltrials.gov NCT00827021
Background
Anemia affects almost all patients with end-stage kidney
disease (ESKD) receiving renal replacement therapy [1].
Established treatment options for anemia of chronic kid-
ney disease (CKD) are Erythropoietin Stimulating Agents
(ESA), including erythropoietins (EPO alfa, beta), darbe-
poetin (DARBO α), pegylated epoietin (continuous
erythropoietin receptor activator, CERA) and biosimilar
epoetins. Observational studies suggest that, compared
to patients with chronic kidney disease whose haemoglo-
bin (Hb) levels are on average 11 g/dL, CKD patients with
Hb levels < 11 g/dL experience a 20-70% higher risk of
death and a 20-40% higher risk of hospitalization [2] and
CKD patients with Hb levels > 12 g/dL have a 15-20%
lower risk of hospitalization with no survival advantage
[3]. However these studies, due to their observational
design, can only establish an association between Hb and
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between Hb levels and risk of death or hospitalizations.
Randomized clinical studies have consistently shown
that Hb targets of 12.0-13.5 g/dL achieved with ESA
cause an increase in adverse vascular events compared to
Hb levels of 10-12 g/dL achieved with the same agents or
no treatment [4-6]. A recent meta-analysis [7], including
9 trials (5143 patients), concluded that patients who
achieve Hb targets around 12.5-13.5 g/dL with ESA have
a 17% higher risk of death (95% confidence intervals (CI)
1%-35%) compared to those who achieve lower Hb tar-
gets (< 12 g/dL) with the same agents. The excess risk of
death is mainly due to an increased rate of adverse vascu-
lar outcomes (which increased by 25%, 95% CI 9-42%).
This meta-analysis was dominated by three large multi-
center randomized trials: the "Normal Hematocrit Study"
[4] (NHS, n = 1233), which enrolled patients receiving
hemodialysis, the "Correction of Hemoglobin and Out-
comes In Renal insufficiency" study (5) (CHOIR, n =
1432) and the "Cardiovascular Risk reduction by Early
Anaemia Treatment with Epoietin beta" study [6] (CRE-
ATE, n = 603) both conducted in patients with CKD not
receiving dialysis. These individual studies and their
pooled analysis, found that higher Hb targets (13.0-15.0
g/dL) achieved with ESA, compared to giving ESA to
achieve lower Hb targets (10.5-11.5 g/dL), caused either
an increased risk of death for cardiovascular events
(CHOIR: relative risk (RR) 1.34; CI 95%:1.03-1.74) or, at
best, no reduction in the risk (CREATE: RR 0.78; CI 95%:
0.53-1.14). In summary, based upon these data, it was
concluded that administering ESA to achieve Hb targets
> 12.5 g/dL caused an increased risk of all-cause mortal-
ity (RR 1.17; CI 95%: 1-13.5; p = 0.031) compared to
administering ESA to achieve Hb targets between 9.0 and
12.0 g/dL.
The clinical practice patterns for management of anae-
mia of CKD still remain highly variable with conflicting
recommendations from key guideline agencies relating
both to optimal Hb targets (Table 1), ESA administration
(including the Hb concentration at which patients should
begin ESA treatment or have their ESA dose adjusted),
iron management and other aspects of ESA treatment
(including definitions of ESA resistance, role of inflam-
mation in management of anaemia, etc.). The variability
in clinical practice and guideline statements prompted
several systematic reviews and design and conduct of
additional randomized trials However, a key question
that remains unanswered is what is the mechanism by
which higher Hb targets cause harm. The uncertainty
regarding optimal anemia management in patients with
chronic kidney disease is compounded further by the
recent release of the results of the "Trial to Reduce Car-
diovascular Events with Aranesp Therapy (TREAT)" [8].
This trial, conducted in 4038 patients with diabetes and
early CKD, who were not yet receiving dialysis, found
that darbepoetin alfa 'does not beat placebo' for the com-
posite endpoint of survival and non fatal cardiovascular
events (RR 1,05; CI 95%: 0,94-1,17; p = 0,41). In addition,
darbepoetin alfa may cause harm (significant increase in
the risk of stroke, RR 1.92; CI 95%: 1.38-2.68; p < 0,001)
with no significant quality of life advantage [5,8].
Taken together, these data showing increased harm and
limited evidence for benefit bring anemia management in
chronic kidney disease back to its origins. Initially, ESA
were introduced to treat anemia in patients with ESKD
receiving hemodialysis for renal replacement therapy, and
who required red blood cell transfusions to elevate
severely reduced hemoglobin levels. Given this identified
benefit of ESA treatment, namely a significant reduction
in the rate of transfusion [8], the question of potential
treatment efficacy was expanded and explored in the pre-
dialysis setting where subsequently no beneficial effects
and the potential for harm have been clearly demon-
strated. In light of the absence of benefit from targeting
hemoglobin levels for patients with CKD, it is now
important to understand whether alternative therapeutic
strategies to manage anaemia in CKD can be found and
whether a fixed dose ESA strategy (high or low) might
increase hemoglobin levels without signifcant harm
(adverse vascular events and mortality).
The mechanism by which targeting Hb levels above
12.5 g/dL causes an increase in the risk of death and car-
diovascular events remains uncertain. It is possible that
the ESA dose required to achieve and maintain higher Hb
targets is directly linked with adverse events, most partic-
ularly in patients who are resistant to the actions of
administered ESA [9,10]. Further, evaluating differing
fixed doses of ESA is difficult because Hb levels inextrica-
bly link to ESA dose and demonstrably affect patient out-
comes.
Trial Hypothesis
We will test the hypothesis that fixed doses of ESA are
feasible and provide improvements in clinical events and
quality of life in individuals with end-stage kidney dis-
ease, without increasing adverse outcomes. The Clinical
Evaluation of the DOSe of Erythropoietins (C.E. DOSE)
trial is the first study to test this hypothesis and assess the
feasibility of two therapeutic strategies for the manage-
ment of anemia in ESKD. The trial has two therapeutic
strategies. These are two fixed ESA doses. The first is
based on the prescription of a minimum ESA dose (4000
I/U per week) and the second is based on the administra-
tion of a maximum ESA dose (18000 I/U per week), inde-
pendent of the Hb target level which is achieved. Both
strategies include a rescue mechanism for dose tapering
when Hb levels fall outside the range of 9,5 to 12,5 g/dL.
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1) To evaluate the comparative efficacy of two fixed 
ESA doses (high versus low) on a composite of major 
cardiovascular endpoints and on safety endpoints;
2) to evaluate the effects of two fixed ESA doses on 
quality of life in hemodialysis patients by means of a 
validated quality of life assessment tool;
3) to evaluate the feasibility of each of the fixed-dose 
therapeutic strategies; and




Patients > 18 years who fulfil the following criteria:
1) Presence of anemia related to ESKD. Anemia is 
defined by the National Kidney Foundation as having 
a Hb level below 12.0 g/dL in women and 13.5 g/L in 
men. In the interest of a common definition for 
recruitment in the C.E. DOSE trial, any patient who is 
already receiving ESA will be eligible for randomiza-
tion, as well as any patient in which the managing 
physician would initiate ESA treatment. Patients will 
be excluded if they have a Hb > 10 g/dL and are not 
currently receiving ESA treatment. For these individ-
uals, ESA initiation would not be recommended 
based on current evidence;
2) Renal replacement therapy with hemodialysis 
(bicarbonate dialysis, hemofiltration, hemodiafiltra-
tion, on-line hemodiafiltration, or acetate-free biofil-
tration);
3) No contraindication to ESA treatment.
Patients who are already receiving treatment with any
ESA may participate in the trial and will be directly
enrolled and randomized into the trial without a wash-
out period. This study will be conducted in agreement
with the Declaration of Helsinki. Patients will provide
written informed consent before commencement of the
study. The following Ethics Committee approved the
study: Comitato indipendente di etica medica dell'AUSL
BR/1 di Brindisi, Italy.
Study design
This will be a pragmatic, multicenter, centrally random-
ized, controlled trial (Figure 1) based upon the intention-
to-treat principle. To achieve allocation concealment,
randomization will be carried out centrally by the coordi-
nating study center. Independent of baseline Hb level,
participants will be allocated to ESA 4000 IU/week intra-
venously versus 18000 IU/week intravenously of erythro-
poietin alfa, beta, or equivalent doses of any other
commercially available agent (including darbepoetin alfa,
C.E.R.A. or biosimilars and other agents, which may
Figure 1 Flow chart describing the selection, randomization and 
follow-up process of the Clinical Evaluation of the Dose of Eryth-
ropoietins (C.E. DOSE) trial.
Randomization 
4000 IU/week iv. EPO alfa or 
beta or equivalent doses of any 
other ESA  
 
 
18000 IU/week iv. EPO alfa or 




Assessment of clinical outcomes  
(composite of major cardiovascular events, 
cardiovascular mortality, safety of 
treatments), quality of life, and costs 
 
Male or female individuals (age ≥18 
years) with ESKD, receiving 
hemodialysis, treated with ESA or 
without side effects to ESA treatment 
Assessment of clinical outcomes  
(composite of major cardiovascular events, 
cardiovascular mortality, safety of 
treatments), quality of life, and costs 
 
Table 1: Guidelines on hemoglobin (Hb) targets in patients with CKDa.
Guidelines Country Year Target Hb level (g/L)
European medicines Agency (EMEA) Europe 2008 100-120
National Kidney Foundation-Dialysis Outcome Quality Initiative (NKF-DOQI) USA 2007 110-120
Italian Society of Nephrology Italy 2006 110-115
100-105b
British Renal Association (BRA) UK 2006 105-125
Canadian Society of Nephrology (CSN) Canada 2008 100-120
European Best Practice Guidelines&(EBPG) Europe 2004 > 110c
Caring for Australasians with Renal Impairment (CARI) Australia 2008 < 130d
a Hb, hemoglobin; CKD, chronic kidney disease
b In patients with cardiovascular disease
c Hb levels > 120 g/L are not recommended for patients with severe cardiovascular disease unless continuing severe symptoms dictate otherwise
d In many patients Hb of 110 g/L may be a suitable therapeutic target nadir
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enrolling center and treatments will be assigned by ran-
dom permuted blocks of six patients.
As there are no previous studies relating to the bene-
fits/harms of different ESA doses for the anemia of ESKD,
we established two fixed experimental doses according to
the following criteria, based upon available data:
1. In the antecedent Hb target trials conducted in CKD
patients [4-6], patients randomized to high (12-14 g/dL)
and low (9.5-11.5 g/dL) Hb targets received between
20000 to 30000 IU/week and between 0 to 10000 g/dL IU/
week of EPO, respectively.
2. In the 2004 United States Renal Data System report,
50% of hemodialysis patients incident to ESRD therapy in
1998 and followed for one year, had Hb levels between
10-13 g/dL and received more than 13000 IU/week of
EPO, in particular 25% received from 13.944 to 21692 IU/
week and 25% more than 21.692 IU/week of EPO [11].
Based on these assumptions the two selected experi-
mental doses will maximize study efficacy. We will also
have a safety mechanism within the trial to ensure that,
after allocation to treatment, Hb values do not fall outside
the safety range (of 9.5 g/dL-12.5 g/dL). A hemoglobin
value above or below this range will trigger a change in
the ESA dose. The prescribed ESA dose will be gradually
increased or decreased by 25% until Hb values return to
between 9.5 and 12.5 g/dL.
We expect recruitment to last 12 months and follow-up
will be completed after 1194 cardiovascular events have
occurred, which is expected to be approximately 4 years
after the last patient is enrolled.
During follow up, patients will receive (in a non-ran-
domized fashion) additional co-interventions (e.g. iron,
lipid lowering agents, bone disease agents, antihyperten-
sive agents, etc.) as per their usual attending physician's
practice to achieve and maintain standard dialysis clinical
performance measures, relating to key CKD-related
comorbidities. Non-randomized targets will include; Kt/
V ≥ 1.3, serum albumin > 35 g/L, nPCR > 1.0 g/kg/day,
ferrum 200-500 μg/L, transferrin saturation 30-40%, cal-
cium 8.4-9.5 mg/dL, phosphorus 3.5-5.5 mg/dL, PTH
150-300 pg/mL, systolic pressure (predialysis) ≤ 140
mmHg, diastolic pressure (predialysis) ≤ 90 mmHg, aver-
age interdialytic weight gain for month ≤ 4% of dry
weight, dialysis blood flow rate > 300 mL/min, LDL < 100
mg/dl, HDL ≥ 40 mg/dl, total cholesterol < 175 mg/dl,
triglycerides < 180 mg/dl.
At the time of randomization, at months 1, 2 and 3, and
at every 6 months thereafter, scheduled trial follow-up
visits will be performed. The incidence of all events (out-
comes) will be measured and minimum clinical workup
and laboratory indicators according to standard clinical
practice will be ascertained. Figure 2 shows a summary of
the key practical aspects of this study.
Study Outcomes
This study will be based upon use of the Prospective Ran-
domized Open Blinded End-Point (PROBE) technique
[12]. According to the PROBE design, an independent
End-Point Committee of medical specialists within the
disease of interest will be established. These physicians
will be unaware of allocated treatment and will review all
available documents (including charts, death certificates,
etc.) to provide a blinded adjudication of all outcomes.
Efficacy of the two experimental interventions (fixed high
dose versus fixed low dose) will be compared by review-
ing the following outcomes: a) clinical efficacy outcomes;
b) quality of life outcomes; c) clinical feasibility outcomes,
and d) costs.
Assessment of clinical efficacy and safety
The clinical efficacy assessment will include evaluating
effects of the two fixed ESA doses on the composite of all-
cause mortality, non fatal stroke, non fatal myocardial
infarction, and hospitalization for acute coronary syn-
drome, transient ischemic attack, non-planned coronary
revascularization procedures and peripheral revascular-
ization procedures. In addition, secondary clinical end-
points will include each component of the primary end-
point, cardiovascular mortality, vascular access thrombo-
sis, and other safety measures, including seizures and
hypertension.
Quality of life assessment
Quality of life (QoL) will be assessed at baseline and every
six months thereafter by administration of the KDQOL-
SF™ 1.3 questionnaire. This self-administered tool
includes 2 QoL instruments, the SF36 and the KDQOL,
which are generic and CKD-specific QoL measures,
respectively. The KDQOL-SF™ 1.3 questionnaire consists
of 18 scales: 8 from the SF-36 questionnaire [13,14]
(physical function, role limitations caused by physical
health problems, role limitations caused by emotional
health problems, bodily pain, general health perception,
vitality, social activities, and mental health) and 10 from
the KDQOL questionnaire [15] (symptoms, effects of
kidney disease on daily life, work status, cognitive func-
tion, quality of social interaction, sexual function, sleep,
social support, patient satisfaction).
Clinical feasibility assessment and cost-efficacy analysis
The clinical feasibility of the two therapeutic strategies
will be assessed by reviewing the following: number of
patients in each arm who maintain stable Hb levels
between 10.0 and 12 g/dL, without need for > 50% change
in the allocated dose of ESA; number of ESA dose varia-
tions from time of randomization to time of Hb level sta-
bilization (between 10.0-12.0 g/dL); average variation of
allocated ESA dose (IU/week for erythropoietins or
microgram/week for darbepoetin) in the two arms; aver-
age ESA dose variation based on weight and body mass
index; time from randomization to the first ESA dose
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tion (between 10.0-12.0 g/dL); number of blood transfu-
sions and number of patients requiring one or more
blood transfusion.
In addition the cumulative in-centre and out-centre
costs of managing dialysis patients allocated to the high
versus low fixed ESA doses will be assessed in a subset of
the overall population.
Figure 2 Summary of key practical aspects of the Clinical Evaluation of the DOSe of Erythropoietin (C.E.DOSE) trial.
 
POTENTIALLY ELIGIBLE 
- Male/ female ≥ 18 years 
- Subjects with ESKD and anemia, receiving renal replacement therapy (low or high flux bicarbonate dialysis, 
hemofiltration, hemodiafiltration, on-line hemodiafiltration, acetate-free biofiltration) 
- Subjects without contraindications to ESA treatment or already receiving treatment with any ESA 
 
RANDOMIZATION VISIT (time 0) 
- Written informed consent 
- Patient clinical history  
- Randomization and treatment allocation 
- Blood chemistry: red blood cells count, HCT, MCV, MCH, MCHC, RDW, MPV, Pct, PDW, platelets  
   lipid profile, glycemic profile, assessment of liver and kidney functions  
- Assessment of hemoglobin levels  
- Measurement of systolic and diastolic blood pressure, measurement of heart rate  
- Assessment of comorbidities 
- Detailed information on dialysis (nPCR, Kt/V, dry weight, interdialytic weight gain, dialysis blood flow rate, 
duration and type of dialysis, type of filter) 
- Detailed information on intradialysis and/or house cointervention on ESKD 
- Detailed assessment of concomitant medication use (trade name, dose, indication) 
- Quality of life questionnaire  
 
FOLLOW-UP VISIT AT MONTHS 1, 2, 3  
- Blood chemistry: Htc, MCV, MCH, MCHC, platelets 
-  Measurement of systolic and diastolic blood pressure, measurement of heart rate 
- Detailed information on dialysis (nPCR, Kt/V, dry weight, interdialytic weight gain, dialysis blood flow rate, 
duration and type of dialysis, type of filter) 
- Detailed information on intradialysis and/or house cointervention on ESKD 
- Detailed assessment of concomitant medication use (trade name, dose, indication) 
- Assessment of haemoglobin level after treatment allocation. For Hb level <9.5 g/dL or >12.5 g/dL (double 
measurement) ESAs’ dose will be changed according to clinical practice (gradual increase or decrease by 
25%). For example look at the therapeutic algorithm (related to erythropoietin or darbepoietin that can be 
extended to other epoietin) in the protocol. 
 
FOLLOW-UP VISIT AT MONTHS 6, 12, 18, 24, 30, 36, 42, 48  
-  Blood chemistry: red blood cells count, HCT, MCV, MCH, MCHC, RDW, MPV, Pct, PDW, platelet 
lipid profile, glycemic profile, assessment of liver and kidney functions  
- Assessment of haemoglobin levels 
- Measurement of systolic and diastolic blood pressure, measurement of heart rate 
- Detailed information on dialysis (nPCR, Kt/V, dry weight, interdialytic weight gain, dialysis blood flow rate, 
duration and type of dialysis, type of filter) 
- Detailed information on intradialysis and/or house cointervention on ESKD  
- Assessment of haemoglobin level after treatment allocation. For Hb level <9.5 g/dL or >12.5 g/dL (double 
measurement) to change ESAs’ dose according to clinical practice (gradual increase or decrease of 25%). 
For example look at the therapeutic algorithm (related to erythropoietin or darbepoietin that can be extended 
to other epoietin) in the protocol. 
- Quality of life questionnaire  
 
MONITORING OF SAFETY AND EFFICACY 
- Open central monitoring of safety and efficacy by an independent Data Safety and Monitoring Committee 
(DSMC) and blinded qualitative monitoring of outcome by an End-point Commitee 
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Sample size
The sample size for the C.E.DOSE trial is estimated based
on the following assumptions:
a) Annual incidence of the primary composite end-
point of 15%, based upon data from existing trials 
[5,16];
b) Expected relative risk reduction in the primary 
composite end-point with the experimental interven-
tion (low ESA dose) of 15% (hazard ratio = 0.85) 
based upon evidence from randomized trials showing 
increased risk of death and adverse vascular out-
comes in higher Hb levels of approximately 15% [7];
c) 80% power using an alpha of 0.05;
d) A dropout rate of 5%.
Given these assumptions, 2204 individuals will be
recruited. If fewer patients are randomized or the event
rate of the primary endpoint is lower than expected, the
duration of follow-up will be extended.
Data analysis
Analysis will be by the intention-to-treat principle. The
incidence rate of events in the high dose versus the low
dose ESA groups will be estimated using Kaplan-Meier
curves. Log-rank test will be used to compare the two
curves [17].
Additional multivariate analyses will be performed
using a Cox proportional hazards model [17]. The pro-
portional hazards assumption will be checked by graphi-
cal inspection of log (-log [survival]) plot. Analyses will be
performed for assessment of the efficacy of study inter-
ventions (high doses or low doses of ESA) on any of the
end-points of this study, including quality of life and
costs. The treatment effect on outcomes, quality of life,
and costs will be also evaluated through subgroup-analy-
sis based upon a series of potential effect modifiers (base-
line information) including socio-demographic factors
(gender, age, ethnicity, marital status, education, occupa-
tional status), presence or absence of cardiovascular risk
factors (diabetes mellitus, hypertension, cigarette smok-
ing, family history of cardiovascular disease), presence or
absence of previous major cardiovascular event, presence
or absence of other major concomitant illness, type of
ESA administered, average ESA dose administered dur-
ing the study, metabolic control (quartiles of total/LDL/
HDL-cholesterol and HbA1c), other cointerventions
(iron, vitamin D or vitamin D analogues, phosphate bind-
ers, calcimimetics, antihypertensive agents, statins, anti-
coagulants), baseline and end of treatment levels of
calcium, phosphorus, iron, parathyroid hormone; Kt/V,
dry weight, dialysis blood flow rate, interdialytic weight
gain, type of dialysis (bicarbonate-dialysis, high versus
low flux, hemodiafiltration, online hemodiafiltration,
hemofiltration, acetate-free biofiltration), dialysis dura-
tion (minutes per dialysis session) and dialysis vintage
(months). Existing trends in the efficacy based upon
these subgroup analyses will be tested with the Mantel-
Haenszel test for each of these covariates. A chi-square
test will be used to assess heterogeneity of observed
effects of interventions.
Interim analysis
A single interim analysis will be performed at two years
after completion of enrolment. The study is event-driven
and in the interim analysis data will be analyzed to assess
the appropriateness of the study hypotheses for sample
size calculations. Should the expected event rates and the
expected risk reduction in the outcome with the experi-
mental intervention be higher or lower than was
assumed, the duration of follow-up will be modified
accordingly. The Data Safety Monitoring Committee will
inform Steering Committee members if they believe that
there is "no further doubt" of an existing net difference
between the experimental and control intervention with
regards to efficacy for the primary endpoint or if there is
any novel evidence indicating that the management of
patients enrolled in the study should change. An existing
net efficacy difference implies at least 3 standard devia-
tions excess or deficit in the interim analysis for the risk
of the primary end-point, which could justify interrup-
tion of the study or modification of the study protocol.
The Steering Committee will therefore decide if the study
needs to be modified or further data are necessary.
Discussion
On the basis of current evidence, the optimal therapeutic
strategy for the management of anemia of ESKD is still
unclear. In light of evidence of increased harm and lim-
ited benefit from targeting Hb levels, Hb target trials are
no longer necessary. The C.E.DOSE study is the first
study to test a new therapeutic approach for the manage-
ment of anemia of ESKD, based on fixed ESA dose. We
will compare the effects of two fixed ESA doses, a maxi-
mum vs a minimum dose, in order to shed light on the
optimal intervention for anemia of hemodialysis patients
improving cardiovascular events, quality of life and costs.
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